vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
T Stamp Inc is the larger business by last-quarter revenue ($908.9K vs $706.0K, roughly 1.3× Astria Therapeutics, Inc.). T Stamp Inc runs the higher net margin — -279.9% vs -4482.0%, a 4202.1% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
ATXS vs IDAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $908.9K |
| Net Profit | $-31.6M | $-2.5M |
| Gross Margin | — | — |
| Operating Margin | -4830.6% | -224.9% |
| Net Margin | -4482.0% | -279.9% |
| Revenue YoY | — | -39.3% |
| Net Profit YoY | -29.0% | 57.7% |
| EPS (diluted) | $-0.55 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $908.9K | ||
| Q3 25 | $706.0K | $872.5K | ||
| Q2 25 | — | $812.7K | ||
| Q1 25 | — | $545.5K | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $0 | $511.1K | ||
| Q2 24 | — | $500.4K | ||
| Q1 24 | — | $573.7K |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-31.6M | $-1.9M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | — | $-6.0M | ||
| Q3 24 | $-24.5M | $-1.3M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | — | -224.9% | ||
| Q3 25 | -4830.6% | -203.0% | ||
| Q2 25 | — | -207.0% | ||
| Q1 25 | — | -396.5% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | — | -523.7% | ||
| Q2 24 | — | -524.7% | ||
| Q1 24 | — | -496.7% |
| Q4 25 | — | -279.9% | ||
| Q3 25 | -4482.0% | -219.1% | ||
| Q2 25 | — | -210.7% | ||
| Q1 25 | — | -395.5% | ||
| Q4 24 | — | -401.5% | ||
| Q3 24 | — | -245.7% | ||
| Q2 24 | — | -519.3% | ||
| Q1 24 | — | -466.9% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-0.55 | $-0.72 | ||
| Q2 25 | — | $-0.69 | ||
| Q1 25 | — | $-0.89 | ||
| Q4 24 | — | $-3.14 | ||
| Q3 24 | $-0.42 | $-1.06 | ||
| Q2 24 | — | $-3.19 | ||
| Q1 24 | — | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $8.7M |
| Total Assets | $271.9M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.0M | ||
| Q3 25 | $227.7M | $5.4M | ||
| Q2 25 | — | $292.1K | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $344.3M | $598.0K | ||
| Q2 24 | — | $659.5K | ||
| Q1 24 | — | $816.7K |
| Q4 25 | — | $8.7M | ||
| Q3 25 | $233.3M | $6.1M | ||
| Q2 25 | — | $2.4M | ||
| Q1 25 | — | $4.1M | ||
| Q4 24 | — | $3.0M | ||
| Q3 24 | $341.7M | $5.4M | ||
| Q2 24 | — | $750.4K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | $11.2M | ||
| Q3 25 | $271.9M | $11.2M | ||
| Q2 25 | — | $5.7M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | $361.6M | $10.6M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | $2.0M |
| Free Cash FlowOCF − Capex | — | $2.0M |
| FCF MarginFCF / Revenue | — | 215.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | $-32.3M | $-4.0M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-1.5M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-28.0M | $-2.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-28.0M | $-2.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | — | 215.4% | ||
| Q3 25 | — | -459.6% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -289.2% | ||
| Q4 24 | — | -182.9% | ||
| Q3 24 | — | -475.4% | ||
| Q2 24 | — | -320.9% | ||
| Q1 24 | — | -376.6% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
